Sun’s Ranbaxy Buy Out Could Have Implications For Nexium Generics
This article was originally published in PharmAsia News
Executive Summary
Ranbaxy’s ability to launch generic versions of AstraZeneca’s blockbuster Nexium in the U.S. on May 27 was uncertain already. Sun’s proposed $4 billion acquisition of Ranbaxy could further distract the troubled Indian generics firm from achieving that goal.
You may also be interested in...
Pfizer Expects OTC Nexium Will Launch With Market Exclusivity
Marketing exclusivity would be a key advantage as Nexium 24HR enters a crowded market of branded and private label OTC competitors. The NDA for Nexium 24HR included clinical data, Pfizer says, but whether FDA allowed Hatch-Waxman Act exclusivity for the product is not yet determined.
Nexium Direct: AstraZeneca’s Ambitious Test Of Direct-To-Consumer Sales
Nexium will ship directly to patients as the drug is about to become victim to generic competition, signaling AstraZeneca’s satisfaction with its Arimidex program.
AstraZeneca’s Promise To Investors: 10 New Drugs By 2020
CEO Pascal Soriot said the big pharma is on track to return to growth faster than anticipated, with 2017 revenues expected to be in line with 2013. A key driver of growth will be new drugs, many of which have been gained through deal-making and acquisitions.